Alyeska Investment Group L.P. Invests $14.95 Million in Medpace Holdings, Inc. (NASDAQ:MEDP)

Alyeska Investment Group L.P. bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 45,000 shares of the company's stock, valued at approximately $14,950,000. Alyeska Investment Group L.P. owned 0.14% of Medpace as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Pallas Capital Advisors LLC raised its stake in shares of Medpace by 179.7% in the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company's stock worth $1,086,000 after purchasing an additional 2,101 shares during the last quarter. Barclays PLC raised its position in Medpace by 71.9% in the 3rd quarter. Barclays PLC now owns 19,781 shares of the company's stock valued at $6,603,000 after buying an additional 8,275 shares during the last quarter. Sanctuary Advisors LLC lifted its stake in Medpace by 20.5% during the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock valued at $1,738,000 after acquiring an additional 844 shares in the last quarter. SYM FINANCIAL Corp purchased a new position in Medpace during the 4th quarter worth $320,000. Finally, Tokio Marine Asset Management Co. Ltd. bought a new stake in shares of Medpace in the 4th quarter worth $9,335,000. 77.98% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Mizuho reduced their price objective on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research report on Wednesday, April 9th. Leerink Partners assumed coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target for the company. William Blair reissued a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. Leerink Partnrs raised shares of Medpace to a "hold" rating in a report on Monday, March 24th. Finally, Robert W. Baird decreased their price objective on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Medpace has a consensus rating of "Hold" and an average price target of $349.30.

Medpace Stock Performance

NASDAQ MEDP traded up $10.93 during trading hours on Wednesday, hitting $299.70. The company had a trading volume of 457,029 shares, compared to its average volume of 346,269. The firm has a 50 day simple moving average of $307.83 and a 200 day simple moving average of $329.16. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $459.77. The firm has a market capitalization of $8.61 billion, a price-to-earnings ratio of 23.73, a PEG ratio of 3.81 and a beta of 1.55.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. The business had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same quarter in the prior year, the firm posted $3.20 EPS. On average, research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Activity at Medpace

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the company's stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the transaction, the director now directly owns 2,998 shares in the company, valued at approximately $904,856.36. The trade was a 36.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 20.30% of the stock is owned by corporate insiders.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.